Therefore, although the underlying mechanisms of SGLT-2 inhibitor in CAVD remained unexplored at the moment, with the advancement of experiments and clinical studies, SGLT-2 inhibitor would probably be one of the promising treatment options for CAVD with ability to attenuate ASCVD independent of glucose control (Figure 3). Here, SLC5A2 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.